title: Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
abstract: BACKGROUND
  Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment.
  
  
  METHODS
  Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be effective and safe, with no clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations. Expert commentary: Calcipotriene plus BD is more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. It should be considered a first line therapy for mild-to-moderate plaque psoriasis.
authors.affiliation: a College of Osteopathic Medicine , Touro University Nevada , Henderson , NV , USA.
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Kin
authors.affiliation: b Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
authors.forename: Dane
authors.initials: D
authors.lastname: Hill
authors.affiliation: b Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.|c Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.|d Department of Public Health Sciences , Wake Forest School of Medicine , Winston-Salem , NC , USA.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000279:Administration, Cutaneous; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012536:Scalp Dermatoses / Q000188:drug therapy / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; C517164:betamethasone dipropionate, calcipotriol drug combination; D001623:Betamethasone; D002117:Calcitriol
keywords: Psoriasis; betamethasone dipropionate; calcipotriene; topical